Castle Biosciences (CSTL) Equity Income (2024 - 2026)

Castle Biosciences (CSTL) has 3 years of Equity Income data on file, last reported at $2.0 million in Q1 2026.

• Quarterly Equity Income rose 241.89% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 669.2% YoY) and the FY2025 annual result came in at $1.5 million, up 164.14% from the prior year.
• Equity Income advanced to $2.0 million in Q1 2026 per CSTL's latest filing, from -$1.9 million in the prior quarter.
• The five-year high for Equity Income was $3.6 million in Q3 2025, with the low at -$1.9 million in Q4 2025.
• Average Equity Income over 3 years is $680333.3, with a median of $870000.0 recorded in 2024.
• Year-over-year, Equity Income plunged 434.23% in 2025 and surged 241.89% in 2026.
• Castle Biosciences' Equity Income stood at $555000.0 in 2024, then sank by 434.23% to -$1.9 million in 2025, then surged by 209.0% to $2.0 million in 2026.
• Business Quant data shows CSTL's Equity Income at $2.0 million in Q1 2026, -$1.9 million in Q4 2025, and $3.6 million in Q3 2025.